News

This notice serves as a reminder of key requirements and features of the Arizona Controlled Substances Prescription Monitoring Program (CSPMP).

Mandatory Use:

• As a prescriber, you are required

The FDA has issued a letter to the Federation of State Medical Boards regarding compounded drug products containing retatrutide, which are being promoted for the treatment of chronic weight management

The Board utilizes Outside Medical Consultants for review of complaints before the Board. Please review the full brochure here. The Board is always seeking Outside Medical Consultants from all

Small Business Bill of Rights

Pursuant to A.R.S. § 32-1855.01, in connection with an investigation conducted by the Board, at all reasonable times the Board and its authorized agents may examine

The Drug Enforcement Administration has made our organization aware that they have eliminated the requirement for DATA-waiver registration for professionals to prescribe buprenorphine to treat opioid

The report of issued permits as determined by A.R.S.§32-1829.01.

Spanish FDA Letter to Healthcare Providers - Breast Implant Safety Updates

FDA Letter to Healthcare Providers - Breast Implant Safety Updates

In accordance with A.R.S.§39-171(A) the Board establishes the point of contact for Public Requests Requests

ADHS: Antivirals Available for Use in Arizona with Tiered Approach